At this point, I honestly have no idea. There are several approaches Regen BioPharma could take, so stating anything specific would be speculation. This is why I said my faith in David Koos remains to be seen. It depends on how he treats current shareholders, though both of those options (reverse merger or selling the rights and progressive work to Big Pharma) seem positive for us when considering our current level. A part of why the IND application being approved is such a big deal is because of the opportunities that open up. Looking at it from an acquiring company's perspective, a lot of time and energy can be saved from obtaining a product that has already been through preclinical studies and has proceeded with Phase 1 trials.
News 
Market Data 
Discover 
AI
